NovoCure Limited (NASDAQ:NVCR) Q1 2024 Earnings Call Transcript

Page 3 of 3

Exciting trial, that, of course is based on the 2-THE-TOP data with immune checkpoint inhibitors up and off the ground. And then finally, the financing. We know that we’ve received a bunch of questions about how we were going to retire the convertible debt that we have on the balance sheet on very good terms I’ll underline, but we think with the financing announced this morning, we will have answered those questions and made it very clear how we intend to proceed in our path to profitability. Big thanks [indiscernible]. Thanks to everyone on our team, thanks to our patients and prescribers and there’s a lot more to come in 2024. We look forward to updating you on all the progress in future calls. Have a good day.

Operator: This concludes today’s conference call. Thank you for participating, and you may now disconnect.

Follow Novocure Ltd (NASDAQ:NVCR)

Page 3 of 3